Contact : +1 (888) 308-1808

/

PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

As an early funder of PepGen, we are pleased to share that PenGen has dosed the first person in its Phase 2 trial for Duchenne amenable to skipping exon 51.  Initial data , including safety and dystrophin production, at the 5 mg/kg dose is expected mid-20.

Read the Press Release HERE

The post PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping appeared first on CureDuchenne.

Leave a Reply

Your email address will not be published. Required fields are marked *